Avillion Signs Clinical Co-development Agreement With Merck to Advance Anti IL-17 A/F Nanobody® in Psoriasis

Thursday, March 30, 2017 General News
Email Print This Page Comment
Font : A-A+

LONDON, March 30, 2017 /PRNewswire/ --

Avillion LLP, a co-developer and financier of late-stage pharmaceutical product

candidates, announces that it has signed a clinical co-development agreement with Merck (Darmstadt, Germany), a leading science and technology company, to advance Merck's anti IL-17 A/F Nanobody® in plaque psoriasis.

Anti

IL-17 A/F Nanobody® is an investigational therapy that has completed Phase I development, and is expected to begin Phase II in plaque psoriasis in 2017. Avillion will be responsible for developing anti IL-17 A/F Nanobody® from Phase II through Phase III. Avillion will also finance the clinical programme through to regulatory submission. No financial terms are disclosed.

Allison Jeynes-Ellis, MD, Chief Executive Officer of Avillion, said: "We are delighted to embark on this new clinical co-development project with Merck and its innovative nanobody candidate. This agreement is a further endorsement of our innovative business model and follows the success of our Phase III programme with Pfizer for BOSULIF® (bosutinib) in chronic myeloid leukaemia. We are very encouraged that our collaborative approach to advancing the development of clinical candidates and boosting our partners' R&D productivity is gaining such awareness in the biopharma industry."

"The collaboration announced today with Avillion will allow us to optimally deliver on the potential of IL-17, a compound which could address several areas of unmet need for patients today," said Belén Garijo, member of the Executive Board of Merck and CEO Healthcare . "In parallel, we have several highly-promising priority clinical assets in our pipeline, all of which we must continue to drive in-house. By partnering appropriately, not only can we maintain the internal focus on our R&D innovation strategy, but also maximize other opportunities that emerge from our pipeline."

Anti IL-17 A/F Nanobody® is an investigational bi-specific half-life extended nanobody that is thought to neutralise both IL-17A and IL-17F with the potential to treat inflammatory diseases. Due to the small size and unique structure of Nanobodies®, they could be an ideal building block for a new generation of novel biological drugs. Merck acquired full, exclusive rights to anti IL-17 A/F Nanobody® through a global development and commercialization deal with Ablynx in 2013. 

About Avillion 

Avillion LLP is a drug development company with an innovative business model focusing on the clinical co-development and regulatory approval of late stage pharmaceutical products. Avillion offers a compelling opportunity to partner late-stage therapeutic projects for approval in the US and EU and to accelerate their availability to the market. Our objective is to enable our partners to continue to develop the drug candidates in their pipeline at the highest quality without increasing the burden on their P&L or cash reserves. Avillion can achieve this by incurring 100% of the clinical and regulatory risk, while advancing the development of these late-stage assets in return for milestone payments on the commercialisation of successfully developed products.

Avillion was founded in 2012 in London, UK, and is backed by Abingworth, Clarus Ventures and Royalty Pharma. For more details, please visit: http://www.avillionllp.com  

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

SOURCE Avillion LLP



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook